Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Xiaoliu Zhang
University of Houston, Department: Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
OnVi Biopharm
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The investigator holds an equity interest ((b)(4) share) in the non-publicly traded startup company OnVi Biopharm. OnVi Biopharm has licensed the investigator's FusOn-H2 oncolytic virus technology from the University of Houston. Dr. Zhang is the PI on the R01; the primary aim of the research is to further develop the licensed cancer virotherapy technology. As the aim is development and not validation or human subjects research, the institution considers the conflict to be a minor one at this time. In addition, the PI has not yet received shares from the company.
Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex Virus
Despite recent improvements in standard care, patients with malignant diseases such as pancreatic cancer still have poor prognoses. Oncolytic virotherapy is a promising alternative treatment that may provide therapeutic benefit to these patients. However, there are several major hurdles that can potentially hamper the clinical development of cancer virotherapy. This proposal is designed to test several novel strategies to overcome these hurdles, and if successful, can have a major impact on clinical translation of this exciting therapeutic approach.
Filed on September 01, 2015.
Tell us what you know about Xiaoliu Zhang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Xiaoliu Zhang filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Xiaoliu Zhang | University of Houston | Conflict of Interest | OnVi Biopharm | $0 - $4,999 |
| Xiaoliu Zhang | University of Houston | Conflict of Interest | OnVi BioPharm | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.